Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

Mark Foster Joins Xenocor BOD

Xenocor Inc., developers of the first single-use, fog-free, portable, HD Laparoscopic Imaging System today announced that Mark Foster will join other experienced healthcare executives as part of the Xenocor Board.

“There is incredible potential in this company. Not only does the technology of Xenoscope advance the bar for laparoscopic surgery, but it also makes minimally invasive surgery more accessible. Which is good for everyone. I see every reason for the successful introduction of the Xenocope into the US market and other markets around the world,” said Mark Foster, CEO of Trice Medical and board member of Xenocor. “I look forward to working with this capable, insightful and motivated team.”

About Mark Foster
A versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies, Mr. Foster will provide strategic council to augment current fundraising, production, commercialization and distribution efforts at Xenocor.

Mr. Foster is currently the CEO of Trice Medical a venture-backed company that has a portfolio of products for minimally invasive diagnostic and therapeutic orthopedic procedures.  In his tenure at Trice, he has acquired and integrated two companies, raised over 60M of debt/equity, expanded the employee base from 12 to 100 and drove significant increase in asset value.

He has held senior management positions focused on business development to include fund-raising, licensing, M&A, commercialization and supply chain initiatives at two large, public companies, Smith and Nephew and Boston Scientific.

“It is clear from Mark’s many accomplishments and business acumen that he can see into the heart of a company, comprehend its potential and envision a successful road forward,” said Evan Kelso, CEO of Xenocor. “His insights are invaluable and there is no doubt we will benefit from his expertise and passion in all facets of our business.”

About the Xenoscope
The FDA cleared Xenoscope™, is a single–use, fog-free, High Definition (HD) laparoscopic imaging system, which can easily replace high cost, inflexible legacy technology to deliver advanced quality surgical care to any location worldwide.  The Xenoscope provides both clinical and financial advantages that benefit surgeons, staff, healthcare facilities and most importantly, patients. It is well positioned to replace expensive, inflexible legacy technologies making laparoscopic surgery possible virtually anywhere.


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Broken String Biosciences Strengthens Senior Leadership Team

Bringing significant expertise in their respective fields, Vincent Smith, PhD and Jessica Rich appointments are a key part of Broken String’s strategy to deliver on its Series A goals, which include the continued development of its INDUCE-seq™ DNA break-mapping platform and acceleration of its commercial expansion across global markets.

New Chief Sales Officer at Encare with Focus on Continued Global Expansion

The HealthTech company Encare has recruited Lotta Sellén as the new Chief Sales Officer (CSO). Lotta Sellén has solid experience in the pharmaceutical, healthcare and HealthTech industries.

CorWave Appoints Magalie Durrèche as Chief Financial Officer

Magalie Durrèche will oversee the financial management and participate in the strategic planning and fundraising of CorWave, a company developing and manufacturing a blood pump based on breakthrough technology. She succeeds Zina Hamoumi, who served as Chief Financial Officer for five years before deciding to focus on other projects.

Veracyte Names Dr Phillip G Febbo Chief Scientific Officer and Chief Medical Officer

“Phil G Febbo is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley. “His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world.”

GrayMatters Health Expands US Executive Team, Including Appointment of Dr Aron Tendler as Chief Medical Office

Dr Aaron Tendler is a board-certified psychiatrist based in Palm Beach, Florida, bringing over 20 years of experience as an industry leader researching novel treatments for mental health disorders.

By using this website you agree to accept Medical Device News Magazine Privacy Policy